Imidazo [1, 5-a] pyrazine anti-tumor compound as well as preparation method and application thereof
By developing imidazo[1,5-a]pyrazine anti-tumor compounds as mTOR inhibitors, the problem of poor toxicity and selectivity of existing anti-cancer drugs to normal cells is solved, and effective inhibition of non-small cell lung cancer has been achieved. And reduces the toxicity of the drug.
Patent Information
- Application Number
- CN202411090331.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-09
AI Technical Summary
Existing anti-cancer drugs are toxic to normal cells and have poor selectivity, making it difficult to effectively inhibit the growth of tumors such as non-small cell lung cancer, and there are drug resistance problems.
An imidazo[1,5-a]pyrazine anti-tumor compound was developed as an mTOR inhibitor, prepared by a specific synthetic route and used to inhibit the growth of lung cancer cells.
This compound significantly inhibited the growth of non-small cell lung cancer cells at low doses, and showed little toxicity, no weight loss or death in the A549 nude mouse transplant tumor model, effectively inhibiting tumor growth.
Smart Images

Figure CN118994167A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparation, and relates to an imidazo[1,5-a]pyrazine anti-tumor compound and a preparation method and application thereof. Background Art
[0002] Cancer is a large class of diseases characterized by abnormal cell proliferation and metastasis. The incidence and mortality of cancer have been on the rise. Traditional anti-cancer drugs are mainly cytotoxic drugs. Most of these drugs are non-selective. While killing cancer cells, they will also kill the body's normal cells. They have the disadvantages of poor selectivity, strong toxic side effects, and easy to develop drug resistance.
[0003] With the rapid development of tumor biology and related disciplines, people have gradually realized that the essence of cell carcinogenesis is the unlimited proliferation of cells caused by the dysregulation of cell signal transduction pathways, which has led to a major change in the concept of anti-tumor drug research and development. The focus of research and development is shifting from traditional cytotoxic drugs to specific anti-tumor drugs targeting abnormal signal system targets in tumor cells.
[0004] mTOR is a serine / threonine protein kinase that has been shown to be closely related to the occurrence and development of a variety of human diseases. Inhibiting the mTOR signaling pathway can effectively block the abnormal signal transduction of various growth factors, thereby blocking the occurrence and development of diseases.
[0005] The occurrence and development of many diseases are related to abnormal mTOR signaling, most of which are manifested as overactivation or overexpression of mTOR. Continuous overactivation of mTOR signals will lead to increased cell metabolism, continuous growth and proliferation, extended cell lifespan, and even cell immortalization, which can directly or indirectly induce cancer, metabolic and aging-related diseases. Inhibiting this state can effectively delay or treat diseases such as cancer and cardiovascular damage caused by overactivation of mTOR. Inhibiting the mTOR signaling pathway can block the conduction of multiple abnormal signals, thereby preventing and controlling the occurrence of diseases. Summary of the invention
[0006] The technical problem to be solved by the present invention is to provide an imidazo[1,5-a]pyrazine anti-tumor compound and its preparation method and application in view of the deficiencies in the prior art. The anti-tumor compound is an mTOR inhibitor that can effectively inhibit the growth of tumors such as non-small cell lung cancer and can be used to prepare drugs for treating diseases related to the activation of this target.
[0007] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:
[0008] The present invention discloses an imidazo[1,5-a]pyrazine anti-tumor compound represented by formula I or its stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, pharmaceutically acceptable salts or prodrugs;
[0009]
[0010] Wherein, R is selected from C2-C6 alkyl, halogenated C2-C6 alkyl, C3-C6 cycloalkyl, heterocycloalkyl or aromatic group.
[0011] In some embodiments, R is selected from C3-C5 alkyl, C3-C5 cycloalkyl, or five-membered heterocyclyl.
[0012] In some embodiments, preferably, R is selected from C3 alkyl, C4 alkyl, C5 alkyl, C3 cycloalkyl, C5 cycloalkyl or oxygen-containing five-membered heterocyclic group.
[0013] In some embodiments, further preferably, R is selected from isopropyl, tert-butyl, pentyl, cyclopropyl, cyclopentyl or tetrahydrofuranyl.
[0014] In some embodiments, more preferably, R is selected from isopropyl, tert-butyl, pent-3-yl, cyclopropyl, cyclopentyl or tetrahydrofuran-2-yl.
[0015] In some embodiments, the imidazo[1,5-a]pyrazine anti-tumor compound is selected from any of the following compounds:
[0016]
[0017] Furthermore, the present invention discloses a method for preparing the imidazo[1,5-a]pyrazine anti-tumor compound of the above-mentioned formula I, comprising the following steps:
[0018] Compound 1 and a formic acid compound undergo a first reaction under the action of a first coupling agent and a first base to obtain compound 2; compound 2 undergoes a second reaction under the action of phosphorus oxychloride to obtain compound 3; compound 3 undergoes a third reaction under the action of an iodine reagent to obtain compound 4; compound 4 undergoes a fourth reaction under the action of an aminating agent to obtain compound 5; compound 5 and a boric acid compound undergo a fifth reaction under the action of a palladium catalyst and a second base to obtain an imidazo[1,5-a]pyrazine antitumor compound I;
[0019]
[0020] Wherein, R is selected from C2-C6 alkyl, halogenated C2-C6 alkyl, C3-C6 cycloalkyl, heterocycloalkyl or aromatic group; X is selected from Cl or Br;
[0021] Wherein, the boric acid compound is
[0022] Among them, preferably, R is selected from C3-C5 alkyl, C3-C5 cycloalkyl or five-membered heterocyclic group; further preferably, R is selected from C3 alkyl, C4 alkyl, C5 alkyl, C3 cycloalkyl, C5 cycloalkyl or oxygen-containing five-membered heterocyclic group; further preferably, R is selected from isopropyl, tert-butyl, pentyl, cyclopropyl, cyclopentyl or tetrahydrofuranyl; most preferably, R is selected from isopropyl, tert-butyl, pent-3-yl, cyclopropyl, cyclopentyl or tetrahydrofuran-2-yl.
[0023] In some embodiments, the first coupling agent is any one or a combination of HATU, HOBt, EDCI, BOP and DCC; the first base is any one or a combination of N-methylmorpholine, triethylamine, diethylamine and diisopropylethylamine; the molar ratio of the compound 1 to the formic acid compound, the first coupling agent and the first base is 1.0-1.1:1.0-1.5:2.0-5.0:2.0-5.0; the first reaction has a reaction temperature of 0°C to 60°C.
[0024] In some embodiments, preferably, the first coupling agent is a composition of HOBt and EDCI in any molar ratio, and more preferably a composition with a molar ratio of 1:1; the first base is N-methylmorpholine; the molar ratio of the compound 1 to the formic acid compound, the first coupling agent, and the first base is 1:1.1:3.0:3.0; and the first reaction has a reaction temperature of room temperature.
[0025] The room temperature, unless otherwise specified, is approximately 25°C.
[0026] Wherein, the HATU is 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate; the HOBt is 1-hydroxybenzotriazole; the EDCI is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; the BOP is benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate; and the DCC is dicyclohexylcarbodiimide.
[0027] Wherein, the N-methylmorpholine is abbreviated as NMM; the diisopropylethylamine is abbreviated as DIPEA.
[0028] The solvent used in the first reaction includes but is not limited to dichloromethane, dimethyl sulfoxide, N,N-dimethylformamide, acetonitrile, n-butanol, dioxane, tetrahydrofuran, preferably dichloromethane; there is no special requirement for the amount of the solvent, as long as the raw materials are dissolved and the viscosity is moderate.
[0029] In some embodiments, the molar ratio of the compound 2 to phosphorus oxychloride is 1.0-1.2:3.0-6.0; and in the second reaction, the reaction temperature is 40°C-80°C.
[0030] In some embodiments, preferably, the molar ratio of the compound 2 to phosphorus oxychloride is 1.0:4.0; and in the second reaction, the reaction temperature is 60°C.
[0031] Wherein, a trace amount of N,N-dimethylformamide can be added into the second reaction to catalyze the reaction.
[0032] The solvent used in the second reaction includes but is not limited to acetonitrile, dioxane, and tetrahydrofuran, preferably acetonitrile; there is no special requirement for the amount of the solvent, as long as the raw materials are dissolved and the viscosity is moderate.
[0033] In some embodiments, the iodine reagent is N-iodosuccinimide; the molar ratio of compound 3 to the iodine reagent is 1.0-1.1:1.1-2.0; the reaction temperature of the third reaction is 20°C-80°C;
[0034] In some embodiments, preferably, the iodination reagent is N-iodosuccinimide; the molar ratio of compound 3 to the iodination reagent is 1.0-1.1:1.1-1.5, and more preferably 1.0:1.2; and the reaction temperature of the third reaction is 60-80°C, and preferably 70°C.
[0035] The solvent used in the third reaction includes but is not limited to DMF and DMSO, preferably DMF; there is no special requirement for the amount of the solvent, as long as the raw materials are dissolved and the viscosity is moderate.
[0036] In some embodiments, the aminating agent is aqueous ammonia; and the reaction temperature of the fourth reaction is 90°C to 130°C.
[0037] In some embodiments, preferably, the fourth reaction has a reaction temperature of 110°C.
[0038] Wherein, the concentration of the ammonia water is 28wt%; and the amount of the aminating agent is excessive.
[0039] Wherein, a solvent may or may not be added in the fourth reaction; when a solvent is added in the fourth reaction, the solvent used includes but is not limited to dioxane, isopropanol, tetrahydrofuran, preferably dioxane; there is no special requirement for the amount of the solvent, as long as the raw materials are dissolved and the viscosity is moderate.
[0040] In some embodiments, the palladium catalyst is any one or a combination of tetrakistriphenylphosphine palladium, tert-butylphosphine palladium, dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium, tris(dibenzylacetone)dipalladium and palladium acetate; the second base is any one or a combination of sodium carbonate, potassium carbonate and sodium bicarbonate; the molar ratio of the compound 5 to the boric acid compound, the palladium catalyst and the second base is 1.0-1.2:1.0-2.0:0.04-0.20:2.0-8.0.
[0041] In some embodiments, preferably, the palladium catalyst is dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium; the second base is sodium carbonate; the molar ratio of the compound 5 to the boric acid compound, the palladium catalyst, and the second base is 1.0-1.2:1.0-1.2:0.06-0.12:3.0-5.0, and further preferably is 1.0:1.0:0.08:4.0.
[0042] Wherein, the dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium is abbreviated as PdCl2(dppf); and the tris(dibenzylacetone)dipalladium is abbreviated as Pd2(dba)3.
[0043] Among them, the fifth reaction is a reflux reaction carried out under the protection of an inert gas, and the reaction temperature is determined by the boiling point of the solvent used, and the reaction temperature allows the solvent to reflux; the solvent used includes but is not limited to mixed solvents such as dioxane-water, DMF-water, ethanol-water, ethylene glycol dimethyl ether-water and toluene-water, preferably a mixed solvent of dioxane and water in any volume ratio, and further preferably a mixed solvent of dioxane and water in a volume ratio of 28:7; there is no special requirement for the amount of the solvent, as long as the raw materials are dissolved and the viscosity is moderate.
[0044] Furthermore, the present invention discloses a pharmaceutical composition comprising the above-mentioned imidazo[1,5-a]pyrazine anti-tumor compound represented by formula I or any one of its stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, and one or more pharmaceutically acceptable carriers.
[0045] Specifically, the above-mentioned pharmaceutical composition, the dosage form of the pharmaceutical composition is one or more of subcutaneous injection, intradermal injection, spray, powder aerosol, external solution, lotion, liniment, ointment, plaster, paste, patch, granule, tablet, capsule, liquid preparation.
[0046] The use of the imidazo[1,5-a]pyrazine anti-tumor compound represented by the above-mentioned formula I or its stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, or the above-mentioned pharmaceutical composition in the preparation of mTOR kinase inhibitors is also within the protection scope of the present invention.
[0047] The use of the imidazo[1,5-a]pyrazine anti-tumor compound represented by the above-mentioned formula I or its stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, or the above-mentioned pharmaceutical composition in the preparation of drugs for treating diseases related to mTOR target activation is also within the protection scope of the present invention.
[0048] Specifically, the related disease is non-small cell lung cancer.
[0049] Beneficial effects:
[0050] (1) The imidazo[1,5-a]pyrazine anti-tumor compounds provided by the present invention have not been reported in the literature and are new compounds. The parent ring of the compounds is imidazo[1,5-a]pyrazine. From the proliferation inhibition test of human small cell lung cancer cells A549, the compounds are significantly stronger than the reference substance PI-103. The compounds can effectively inhibit the growth of lung cancer cells A549. Among them, the present invention conducted an in vivo pharmacodynamic evaluation of the NJ-12 compound (1-(2-aminobenzo[d]oxazol-5-yl)-3-isopropylimidazo[1,5-a]pyrazine-8-amine) in an A549 nude mouse transplant tumor model, and found that the NJ-12 compound had a significant inhibitory effect on the tumor at a low dose.
[0051] (2) When the imidazo[1,5-a]pyrazine antitumor compound (NJ-12) provided by the present invention was administered to an A549 nude mouse transplanted tumor model, there was no death or weight loss in the mice 3 weeks after administration, indicating that the imidazo[1,5-a]pyrazine antitumor compound (NJ-12) provided by the present invention has low toxicity. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.
[0053] Figure 1 This is a curve diagram of the inhibition of mTOR kinase by compound NJ-12.
[0054] Figure 2 This is the curve of the mTOR kinase inhibition by the control substance PI-103.
[0055] Figure 3The graph is a graph of the in vivo efficacy (time / tumor volume) of the compound NJ-12 administration group and the solvent control group in the A549 nude mouse transplanted tumor model.
[0056] Figure 4 This is a curve diagram of the compound NJ-12 administration group and the solvent control group after administration to A549 nude mice (time / nude mouse body weight). DETAILED DESCRIPTION
[0057] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the contents described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.
[0058] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.
[0059] Example 1: Synthesis of Compound NJ-12
[0060] The synthetic route of compound NJ-12 is as follows:
[0061]
[0062] (1) Synthesis of N-((3-chloropyrazin-2-yl)methyl)isobutyramide (Compound 2a)
[0063] (3-Chloropyrazin-2-yl)methylamine hydrochloride (5.4 g, 30 mmol) was suspended in dichloromethane (80 mL), and isobutyric acid (2.91 g, 33 mmol), HOBt (6.08 g, 45 mmol), EDCI (8.62 g, 45 mmol) and N-methylmorpholine (9.10 g, 90 mmol) were added, and stirred at room temperature overnight. After the reaction was completed, the reaction solution was concentrated to dryness under reduced pressure, and water (50 mL) and dichloromethane (200 mL) were added for extraction, washed with water (2x100 mL), washed with saturated sodium carbonate solution (100 mL), washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a light yellow solid N-((3-chloropyrazin-2-yl)methyl)isobutyramide, recorded as compound 2a, 4.6 g, 21.5 mmol, yield 71.7%
[0064] Compound 2a was detected by mass spectrometry, EI-MS MS (m / z): 214.3 [M+H] + ; The NMR data of compound 2a are as follows: 1H-NMR (CDCl3, 400MHz): δ8.44(d,J=4.0Hz,1H), 8.30(d,J=4.0Hz,1H), 6.87(br,s,1H), 4.67(d,J=4.0Hz,2H),2.55~2.48(m,1H),1.21(d,J=8.0Hz,3H),1.16(d,J=8.0Hz,3H).
[0065] (2) Synthesis of 8-chloro-3-isopropylimidazo[1,5-a]pyrazine (Compound 3a)
[0066] N-((3-chloropyrazin-2-yl)methyl)isobutyramide (Compound 2a) (1.5 g, 7.0 mmol) was dissolved in acetonitrile (22.5 mL), phosphorus oxychloride (4.3 g, 28.0 mmol) and DMF (3 drops) were added, and the oil bath was heated to 60°C and stirred for 1 hour. After the reaction, the reaction solution was concentrated to dryness under reduced pressure, ice water was added, shaken, extracted with dichloromethane (200 mL), washed with ice water (80 mL) 3 times, washed with saturated brine (80 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a low melting point substance 8-chloro-3-isopropylimidazo[1,5-a]pyrazine, recorded as compound 3a, 840 mg, 4.3 mmol, and a yield of 61.4%.
[0067] Compound 3a was detected by mass spectrometry, EI-MS MS (m / z): 196.3 [M+H] + ; The NMR data of compound 3a are as follows: 1 H-NMR (CDCl3, 400MHz): δ7.80 (s, 1H), 7.62 (d, J = 8.0Hz, 1H), 7.34 (d, J = 8.0Hz, 1H), 3.35 ~ 3.29 (m, 1H), 1.52 (d, J = 8.0Hz, 3H), 1.47 (d, J = 8.0Hz, 3H).
[0068] (3) Synthesis of 8-chloro-1-iodo-3-isopropylimidazo[1,5-a]pyrazine (Compound 4a)
[0069] 8-Chloro-3-isopropylimidazo[1,5-a]pyrazine (Compound 3a) (822 mg, 4.2 mmol) was dissolved in DMF (10 mL), and NIS (1.13 g, 5.04 mmol) was added. The mixture was heated to 70°C in an oil bath and stirred for 3 hours. After the reaction, the reaction solution was concentrated to dryness under reduced pressure, extracted with dichloromethane (200 mL), washed with saturated Na2SO3 solution (50 mL), washed with saturated brine (80 mL) 3 times, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a solid. The solid was purified by silica gel flash column (dichloromethane → dichloromethane: methanol = 80:1) to obtain a pale yellow solid 8-chloro-1-iodo-3-isopropylimidazo[1,5-a]pyrazine, recorded as compound 4a, 1.0 g, 3.11 mmol, yield 74.0%.
[0070] Compound 4a was detected by mass spectrometry: EI-MS MS (m / z): 322.0 [M+H] + ; The NMR data of compound 4a are as follows: 1 H-NMR (CDCl3, 400MHz): δ7.64 (d, J = 4.0Hz, 1H), 7.30 (d, J = 4.0Hz, 1H), 3.27~3.22 (m, 1H), 1.44 (d, J = 8.0Hz, 6H).
[0071] (4) Synthesis of 1-iodo-3-isopropylimidazo[1,5-a]pyrazine-8-amine (Compound 5a)
[0072] 8-Chloro-1-iodo-3-isopropylimidazo[1,5-a]pyrazine (Compound 4a) (380 mg, 1.18 mmol) was placed in a thick-walled pressure-resistant glass bottle, and dioxane (5 mL) and concentrated ammonia (28 wt%, 5 mL) were added, and the oil bath was heated to 110°C and stirred for 7 hours. After the reaction, the reaction solution was cooled, decompressed to dryness, water (50 mL) was added, shaken, filtered, washed with water, and dried to obtain an off-white solid 1-iodo-3-isopropylimidazo[1,5-a]pyrazine-8-amine, recorded as Compound 5a, 270 mg, 0.89 mmol, yield 75.4%.
[0073] Compound 5a was detected by mass spectrometry: EI-MS MS (m / z): 303.1 [M+H] + ; The NMR data of compound 5a are as follows: 1 H-NMR (CDCl3, 400MHz): δ7.23 (d, J = 4.0Hz, 1H), 7.00 (d, J = 4.0Hz, 1H), 3.22 ~ 3.17 (m, 1H), 1.41 (d, J = 8.0Hz, 6H).
[0074] (5) Synthesis of 1-(2-aminobenzo[d]oxazol-5-yl)-3-isopropylimidazo[1,5-a]pyrazin-8-amine (Compound NJ-12)
[0075] 1-iodo-3-isopropylimidazo[1,5-a]pyrazine-8-amine (compound 5a) (580 mg, 1.92 mmol), 2-amino-benzoxazole-5-boronic acid hydrochloride (412 mg, 1.92 mmol), PdCl2(dppf) (110 mg, 0.15 mmol), sodium carbonate (814 mg, 7.68 mmol) and dioxane-water (28 mL-7 mL) were refluxed under nitrogen protection for 7 hours. After the reaction, the reaction solution was cooled and concentrated to dryness. Water (50 mL) was added, and the solid was shaken and filtered to obtain a solid. The solid was purified by silica gel flash column (eluted with dichloromethane: methanol = 10:1) and concentrated to obtain an off-white solid 1-(2-aminobenzo[d]oxazol-5-yl)-3-isopropylimidazo[1,5-a]pyrazin-8-amine, recorded as compound NJ-12, 350 mg, 1.14 mmol, and a yield of 59.4%.
[0076] Compound NJ-12 was detected by mass spectrometry: EI-MS MS (m / z): 309.4 [M+H] + ; The NMR data of compound NJ-12 are as follows: 1 H-NMR (DMSO-d6, 400MHz): δ7.56(d,J=4.0Hz,1H),7.48(s,2H),7.43(d,J=8.0Hz,1H),7.34(s,1H),7. 17(d,J=8.0Hz,1H),7.01(d,J=4.0Hz,1H),5.98(br,s,2H),3.45-3.38(m,1H),1.34(d,J=8.0Hz,6H). 13 C-NMR(DMSO-d6,100MHz): δ163.83,152.14,148.13,145.34,144.42,134.8 3,130.99,127.96,121.95,116.56,113.55,108.75,106.66,25.58,21.07.
[0077] Example 2: Synthesis of 1-(2-aminobenzo[d]oxazol-5-yl)-3-cyclopentylimidazo[1,5-a]pyrazine-8-amine (Compound NJ-10)
[0078]
[0079] The preparation method is the same as that in Example 1, except that the starting material isobutyric acid in step (1) is replaced by cyclopentanecarboxylic acid, and finally 1-(2-aminobenzo[d]oxazol-5-yl)-3-cyclopentylimidazo[1,5-a]pyrazine-8-amine is synthesized, which is recorded as compound NJ-10.
[0080] Compound NJ-10 was detected by mass spectrometry: EI-MS MS (m / z): 335.1 [M+H] + ; The NMR data of compound NJ-10 are as follows: 1 H-NMR (DMSO-d6, 400MHz): δ7.59(d,J=4.0Hz,1H),7.52(s,2H),7.45(d,J=8.0Hz,1H),7.36(s,1H),7.19(d,J=8.0Hz,1H),7.03( d,J=4.0Hz,1H),6.04(br,s,2H),3.57-3.49(m,1H),2.14-2.10(m,2H),1.95-1.90(m,2H),1.82-1.79(m,2H),1.71-1.68(m,2H).
[0081] Example 3: Synthesis of 1-(2-aminobenzo[d]oxazol-5-yl)-3-cyclopropylimidazo[1,5-a]pyrazine-8-amine (Compound NJ-11)
[0082]
[0083] The preparation method is the same as that in Example 1, except that the starting material isobutyric acid in step (1) is replaced by cyclopropylcarboxylic acid, and finally 1-(2-aminobenzo[d]oxazol-5-yl)-3-cyclopropylimidazo[1,5-a]pyrazine-8-amine is synthesized, which is recorded as compound NJ-11.
[0084] Compound NJ-11 was subjected to mass spectrometry detection: EI-MS MS (m / z): 307.3 [M+H] +; the synthesis data of compound NJ-11 are as follows: 1 H-NMR (DMSO-d6, 400MHz): δ7.81(d,J=8.0Hz,1H),7.54(s,2H),7.44(d,J=8.0Hz,1H),7.35(s,1H),7 .19(d,J=8.0Hz,1H),7.08(d,J=8.0Hz,1H),2.42-2.37(m,1H),1.12-1.08(m,2H),1.05-1.03(m,2H).
[0085] Example 4: Synthesis of 1-(2-aminobenzo[d]oxazol-5-yl)-3-(pentan-3-yl)imidazo[1,5-a]pyrazin-8-amine (Compound NJ-13)
[0086]
[0087] The preparation method is the same as that in Example 1, except that the starting material isobutyric acid in step (1) is replaced by 2-ethylbutyric acid, and finally 1-(2-aminobenzo[d]oxazol-5-yl)-3-(pentan-3-yl)imidazo[1,5-a]pyrazine-8-amine is synthesized, which is recorded as compound NJ-13.
[0088] Compound NJ-13 was subjected to mass spectrometry detection: EI-MS MS (m / z): 337.2 [M+H] +; the NMR data of compound NJ-13 are as follows: 1 H-NMR (DMSO-d6, 400MHz): δ7.64(d,J=4.0Hz,1H),7.52(s,2H),7.44(d,J=8.0Hz,1H),7.35(d,J=4.0Hz,1H),7.16(d ,J=8.0Hz,1H),6.99(d,J=4.0Hz,1H),6.01(br,s,2H),3.10-3.08(m,1H),1.81-1.71(m,4H),0.77(t,J=8.0Hz,6H).
[0089] Example 5: Synthesis of 3-tert-butyl-1-(2-aminobenzo[d]oxazol-5-yl)imidazo[1,5-a]pyrazin-8-amine (Compound NJ-14)
[0090]
[0091] The preparation method is the same as that in Example 1, except that the starting material isobutyric acid in step (1) is replaced by 2,2-dimethylpropionic acid, and finally 3-tert-butyl-1-(2-aminobenzo[d]oxazol-5-yl)imidazo[1,5-a]pyrazin-8-amine is synthesized, which is recorded as compound NJ-14.
[0092] Compound NJ-14 was detected by mass spectrometry: EI-MS MS (m / z): 323.4 [M+H] + ; The NMR data of compound NJ-14 are as follows: 1H-NMR(DMSO-d6,400MHz): δ7.75(d,J=4.0Hz,1H),7.52(s,2H),7.46(d,J=8.0Hz,1H),7 .36(s,1H),7.19(d,J=8.0Hz,1H),7.00(d,J=4.0Hz,1H),5.99(br,s,2H),1.52(s,9H).
[0093] Example 6: Synthesis of 1-(2-aminobenzo[d]oxazol-5-yl)-3-(tetrahydrofuran-2-yl)imidazo[1,5-a]pyrazin-8-amine (Compound NJ-15)
[0094]
[0095] The preparation method is the same as that in Example 1, except that the starting material isobutyric acid in step (1) is replaced by tetrahydrofuran-2-carboxylic acid, and finally 1-(2-aminobenzo[d]oxazol-5-yl)-3-(tetrahydrofuran-2-yl)imidazo[1,5-a]pyrazine-8-amine is synthesized, which is recorded as compound NJ-15.
[0096] Compound NJ-15 was detected by mass spectrometry: EI-MS MS (m / z): 337.3 [M+H] + ; The NMR data of compound NJ-15 are as follows: 1 H-NMR (DMSO-d6, 400MHz): δ7.65(d,J=4.0Hz,1H),7.54(s,2H),7.45(d,J=8.0Hz,1H),7.38(d,J=4.0Hz,1H),7.20(d,J=8.0Hz,1H),7.0 9(d,J=8.0Hz,1H),6.09(br,s,2H),5.35(t,J=8.0Hz,1H),3.88-3.85(m,2H),2.66-2.61(m,1H),2.30-2.26(m,1H),2.12-2.00(m,2H).
[0097] Example 7: Detection of the inhibitory activity of compound NJ-12 on mTOR kinase
[0098] The compound NJ-12 prepared in Example 1 was used in this example.
[0099] Experimental methods:
[0100] 1. Reagents
[0101] Kinase buffer: 50 mM HEPES, pH 7.5, 1 mM EGTA, 0.01% Tween-20, 10 mM MgCl2, 3 mM MnCl2.
[0102] 2. Experimental steps:
[0103] The test compound NJ-12 and the reference substance PI-103 were dissolved in DMSO, and the drug solutions of different concentrations were prepared according to a certain starting concentration, such as 10 μM, and diluted 4 times, and added to the enzyme reaction system; DMSO control and no mTOR kinase control were set at the same time. The optimal concentrations of mTOR enzyme, substrate (Ulight-4E-BP1) and ATP were prepared with kinase buffer to prepare the enzyme reaction system; wherein, the enzyme reaction system includes: kinase buffer, ATP (8 μM), kinase substrate (50nM, Ulight-4E-BP1), mTOR kinase (4nM). Different concentrations of drug solutions were added to the enzyme reaction system (the final concentration of the drug in the system is shown in Table 1), and the mixed reaction system was reacted at room temperature for 30 minutes; the pre-treated detection buffer containing EDTA and antibody (Eu-anti-phospho-4E-BP1) was added, centrifuged, and balanced at room temperature for 60 minutes, and the signal data was collected with the Envision instrument, and the numerical ratio of the fluorescence readings (665nm / 615nm) was read. The inhibition rate was calculated according to the following formula: % inhibition rate = (the numerical ratio of the fluorescence reading of the DMSO control - the numerical ratio of the fluorescence reading of the sample) / (the numerical ratio of the fluorescence reading of the DMSO control - the numerical ratio of the fluorescence reading of the control without kinase addition). The curve was fitted using the formula Y = Bottom + (Top-Bottom) / (1 + (IC50 / X)^HillSlope) to obtain the IC 50 value.
[0104] Table 1 Inhibition rate of compound NJ-12 on mTOR kinase at different concentrations
[0105]
[0106] Table 2 Inhibition rate of mTOR kinase by reference substance PI-103 at different concentrations
[0107]
[0108]
[0109] From Table 1, Table 2, Figure 1 , Figure 2 The data show that compound NJ-12 inhibits mTOR kinase with an IC 50 The IC value of the control substance PI-103 for inhibiting mTOR kinase is 3.61nM. 50The inhibitory activity of compound NJ-12 on mTOR kinase target was significantly stronger than that of the reference substance PI-103.
[0110] Example 8: Proliferation inhibition of human small cell lung cancer cell A549 by the test sample
[0111] Compounds NJ-10 to NJ15 prepared in Examples 1 to 6 were used in this example.
[0112] The reference substance PI-103 was purchased commercially.
[0113] 1. Tumor cell culture
[0114] Tumor cell line: Human small cell lung cancer cell A549, derived from the Shanghai Cell Bank of the Chinese Academy of Sciences, was cultured at 37°C in F-12K culture medium containing 10% fetal bovine serum and passaged every 2 to 3 days.
[0115] Preparation of drug solution: Compounds NJ-10 to NJ15 prepared in Examples 1 to 6 and the reference substance PI-103 were mixed with F-12K culture medium to prepare drug solutions with concentrations of 1000 nM, 333 nM, 111 nM, 37.0 nM, 12.4 nM, 4.12 nM, 1.37 nM and 0.457 nM, respectively.
[0116] 2. Alamar Blue method to detect cell proliferation
[0117] 1) Collect A549 cells in the logarithmic phase, adjust the concentration of the cell suspension, plate the cells in a 96-well plate, add 100 μL of the plate to each well to make the cell density of the test cell 3000 / well (the edge wells are filled with pH=7.4, 0.01M PBS, and the cell density is adjusted according to the cell growth rate);
[0118] 2) Incubate at 5% CO2, 37°C until the cells adhere to the wall. After 24 hours, remove the original culture medium solution and add the drug solutions of different concentration gradients prepared above. The concentrations of each drug are 1000nM, 333nM, 111nM, 37.0nM, 12.4nM, 4.12nM, 1.37nM and 0.457nM, respectively. Set up 2 replicate wells for each concentration.
[0119] 3) Incubate the culture plate in an incubator at 37°C for 72 hours;
[0120] 4) Add 22 μL of Lamar Blue (Resazurin) solution to each well;
[0121] 5) Incubate the culture plate in an incubator at 37°C for 5 hours;
[0122] 6) Measure the absorbance (fluorescence intensity) at 530 / 590 nm using an enzyme-labeled instrument.
[0123] 3. Data Analysis
[0124] Graphpadprism software was used to generate graphs and analyze the fluorescence intensity data. IC 50 ,The specific experimental results are shown in Table 3.
[0125] Table 3 Inhibitory effect of the tested samples on proliferation of human small cell lung cancer cell A549 (IC 50 )
[0126]
[0127]
[0128] From the data in Table 3, it can be seen that the prepared NJ series compounds have a significantly stronger inhibitory effect on the proliferation of human small cell lung cancer cells A549 than the reference substance PI-103, among which the inhibitory effect of compound NJ-12 on the activity of A549 cells is about 30 times that of the reference substance PI-103.
[0129] Example 9: In vivo efficacy evaluation of compound NJ-12 in a nude mouse transplanted tumor model of human small cell lung cancer cell A549
[0130] 1. Experimental Materials
[0131] 1.1 Reagents
[0132] F-12K culture medium; fetal bovine serum; penicillin-streptomycin double antibody (100U penicillin and 100ug / mL streptomycin), trypsin (containing 0.25% EDTA), PBS (pH=7.4, 0.01M), etc.
[0133] 1.2 Experimental Animals
[0134] Female BALB / c Nude mice (number: 18; age: 6-8 weeks, weight 20-24g) were purchased from Cavensburg (Suzhou) Model Animal Research Co., Ltd. and kept in the SPF animal room of Suzhou Shengsu New Drug Development Co., Ltd., with a temperature of 20-25°C, a relative humidity of 40%-70%, and 12 hours of light and dark lighting respectively; the animals were free to drink water and eat. After about 5 days of normal feeding, mice with good physical signs were selected for this experiment after veterinary examination. Before grouping, the animal was marked at the base of the tail with a marker pen, and after grouping, each animal was marked by ear cut.
[0135] 1.3 Transplantable Tumor Cells
[0136] Human small cell lung cancer cells A549 were obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences (CAS, frozen in liquid nitrogen in our laboratory).
[0137] 2. Experimental methods
[0138] 2.1 A549 cell culture
[0139] A549 cells were routinely cultured in F-12K complete medium (containing 10% fetal bovine serum and 1% cyan-chain double antibody) under 5% CO2, 37°C and saturated humidity conditions; according to cell growth, cells were washed with PBS and digested with trypsin (containing 0.25% EDTA) for passage 1 to 2 times a week at a passage ratio of 1:3 to 1:6.
[0140] 2.2 Animal Model Preparation
[0141] A549 cells in the logarithmic growth phase were collected, counted, and resuspended in serum-free F-12K medium to adjust the cell concentration to 8×10 7 cells / mL; pipette the cells to disperse them evenly and then put them into a 50-mL centrifuge tube, which was placed in an ice box; use a 1-mL syringe to draw up the cell suspension and inject it into the subcutaneous part of the right axilla of the nude mice. Each animal was inoculated with 100 μL (8×10 6 The A549 nude mouse transplant tumor model was established. The animal status and tumor growth were observed regularly after inoculation. The tumor diameter was measured with an electronic vernier caliper, and the data was entered into an Excel spreadsheet to calculate the tumor volume. When the tumor volume reached 100-300mm 3 Animals in good health and with similar tumor volumes were selected and divided into two groups (n=6) by random block method. The day of grouping was the first day of the experiment (D1). After the start of the experiment, the tumor diameter was measured twice a week, the tumor volume was calculated, and the animal weight was weighed and recorded.
[0142] 2.3 Preparation of drug delivery preparations
[0143] Before each administration, an appropriate amount of compound NJ-12 was weighed, and an appropriate volume of PEG400 was added thereto. The liquid was vortexed to mix evenly to obtain a final concentration of 0.5 mg·mL -1 The dosing preparation was prepared once a week and stored in a 4°C refrigerator.
[0144] 2.4 Animal grouping and drug administration
[0145] Drug administration began on the day of grouping, and was administered orally or by gavage once a day. The dosage was 5.0 mg / kg in the first week and 10.0 mg / kg in the next two weeks. The experiment was terminated after 3 weeks.
[0146] Among them, the solvent control group was given an equal volume of PEG400 to A549 nude mouse transplanted tumor model mice.
[0147] from Figure 3 It can be seen that after administration, compound NJ-12 can significantly inhibit the growth of small cell lung cancer (A549) transplanted tumors in nude mice.
[0148] from Figure 4 It can be seen that after 3 weeks of administration, compared with the body weight of mice in the solvent control group, the body weight of A549 nude mouse transplanted tumor model mice did not decrease after administration of compound NJ-12, and the nude mice did not die, indicating that compound NJ-12 has little toxic side effects.
[0149] The present invention provides an imidazo[1,5-a]pyrazine anti-tumor compound and its preparation method and application idea and method. There are many methods and ways to implement the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the protection scope of the present invention. All components not specified in this embodiment can be implemented by existing technologies.
Claims
1. An imidazo[1,5-a]pyrazine antitumor compound of formula I or its stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, pharmaceutically acceptable salts or prodrugs; in, R is selected from C2-C6 alkyl, halogenated C2-C6 alkyl, C3-C6 cycloalkyl, heterocycloalkyl or aromatic group.
2. The compound according to claim 1, characterized in that R is selected from C3-C5 alkyl, C3-C5 cycloalkyl or five-membered heterocyclic group; Preferably, R is selected from C3 alkyl, C4 alkyl, C5 alkyl, C3 cycloalkyl, C5 cycloalkyl or oxygen-containing five-membered heterocyclic group; Further preferably, R is selected from isopropyl, tert-butyl, pentyl, cyclopropyl, cyclopentyl or tetrahydrofuranyl; Still more preferably, R is selected from isopropyl, tert-butyl, pent-3-yl, cyclopropyl, cyclopentyl or tetrahydrofuran-2-yl.
3. The compound according to claim 1, characterized in that The imidazo[1,5-a]pyrazine anti-tumor compound is selected from any of the following compounds:
4. The method for preparing the imidazo[1,5-a]pyrazine antitumor compound of formula I according to claim 1, characterized in that: The steps include: Compound 1 and a formic acid compound undergo a first reaction under the action of a first coupling agent and a first base to obtain compound 2; compound 2 undergoes a second reaction under the action of phosphorus oxychloride to obtain compound 3; compound 3 undergoes a third reaction under the action of an iodine reagent to obtain compound 4; compound 4 undergoes a fourth reaction under the action of an aminating agent to obtain compound 5; compound 5 and a boric acid compound undergo a fifth reaction under the action of a palladium catalyst and a second base to obtain an imidazo[1,5-a]pyrazine antitumor compound I; Wherein, R is selected from C2-C6 alkyl, halogenated C2-C6 alkyl, C3-C6 cycloalkyl, heterocycloalkyl or aromatic group; X is selected from Cl or Br; Wherein, the boric acid compound is 5. The preparation method according to claim 4, characterized in that: The first coupling agent is any one or a combination of HATU, HOBt, EDCI, BOP and DCC; the first base is any one or a combination of N-methylmorpholine, triethylamine, diethylamine and diisopropylethylamine; the molar ratio of the compound 1 to the formic acid compound, the first coupling agent and the first base is 1.0-1.1: 1.0-1.5: 2.0-5.0: 2.0-5.0; the first reaction has a reaction temperature of 0°C to 60°C; the molar ratio of the compound 2 to phosphorus oxychloride is 1.0-1.2: 3.0-6.0; the second reaction has a reaction temperature of 40°C to 80°C; the iodine reagent is N-iodosuccinimide; the compound 3 The molar ratio of the compound 5 to the iodine reagent is 1.0-1.1:1.1-2.0; the reaction temperature of the third reaction is 20°C-80°C; the aminating reagent is aqueous ammonia; the reaction temperature of the fourth reaction is 90°C-130°C; the palladium catalyst is any one or a combination of tetrakistriphenylphosphine palladium, tert-butylphosphine palladium, dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium, tris(dibenzylacetone)dipalladium and palladium acetate; the second base is any one or a combination of sodium carbonate, potassium carbonate and sodium bicarbonate; the molar ratio of the compound 5 to the boric acid compound, the palladium catalyst and the second base is 1.0-1.2:1.0-2.0:0.04-0.20:2.0-8.
0.
6. A pharmaceutical composition, characterized in that It comprises an imidazo[1,5-a]pyrazine antitumor compound of formula I as described in claim 1 or any one of its stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, and one or more pharmaceutically acceptable carriers.
7. The pharmaceutical composition according to claim 6, characterized in that The dosage form of the pharmaceutical composition is one or more of subcutaneous injection, intradermal injection, spray, powder aerosol, external solution, lotion, liniment, ointment, plaster, paste, patch, granule, tablet, capsule, and liquid preparation.
8. Use of the imidazo[1,5-a]pyrazine antitumor compound of formula I as claimed in claim 1 or its stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, or the pharmaceutical composition as claimed in claim 6 in the preparation of an mTOR kinase inhibitor.
9. Use of the imidazo[1,5-a]pyrazine antitumor compound of formula I as described in claim 1 or its stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, pharmaceutically acceptable salts or prodrugs, or the pharmaceutical composition as described in claim 6 in the preparation of drugs for treating diseases related to mTOR target activation.
10. The use according to claim 9, characterized in that: The related disease is non-small cell lung cancer.
Citation Information
Patent Citations
Fused bicyclic mTOR inhibitors
CN101316845A
Imidazo[1,2-a]pyridine compound, preparation method and applications thereof
CN104370898A
Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
WO2007106503A2
